Hansa Biopharma AB Cash Flow Conversion Efficiency
Hansa Biopharma AB cash flow conversion efficiency. Based on the latest financial reports, Hansa Biopharma AB (HNSA) has a cash flow conversion efficiency ratio of 0.253x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-111.70 Million ≈ $-12.02 Million USD) by net assets (Skr-441.06 Million ≈ $-47.46 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Hansa Biopharma AB (2008–2024)
Cash flow conversion efficiency of Hansa Biopharma AB from 2008 to 2024. This chart illustrates how Hansa Biopharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Hansa Biopharma AB for real-time trading data and today's change.
Hansa Biopharma AB Cash Flow Conversion Ratio Explained
Hansa Biopharma AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Hansa Biopharma AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hansa Biopharma AB ranked by their cash flow conversion efficiency. Also see Hansa Biopharma AB stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Testa Residencial SOCIMI S.A.
MC:YTST
|
N/A |
|
Keck Seng Malaysia Bhd
KLSE:3476
|
0.010x |
|
Shoppers Stop Limited
NSE:SHOPERSTOP
|
1.280x |
|
Viking Tech
TWO:3624
|
0.055x |
|
Wuhan Hiteck Biological Pharma Co Ltd
SHE:300683
|
-0.008x |
|
Miwon Specialty Chemical Co Ltd
KO:268280
|
0.059x |
|
Zhejiang Runyang New Material Technology Co. Ltd.
SHE:300920
|
-0.003x |
|
FinVolution Group
NYSE:FINV
|
0.052x |
Annual Cash Flow Conversion Efficiency for Hansa Biopharma AB (2008–2024)
The table below shows the annual cash flow conversion efficiency of Hansa Biopharma AB from 2008 to 2024. Review Hansa Biopharma AB free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr-589.83 Million ≈ $-63.48 Million |
Skr-674.88 Million ≈ $-72.63 Million |
1.144x | -74.58% |
| 2023-12-31 | Skr-167.88 Million ≈ $-18.07 Million |
Skr-755.65 Million ≈ $-81.32 Million |
4.501x | +639.82% |
| 2022-12-31 | Skr602.91 Million ≈ $64.88 Million |
Skr-502.73 Million ≈ $-54.10 Million |
-0.834x | -31.28% |
| 2021-12-31 | Skr757.57 Million ≈ $81.53 Million |
Skr-481.17 Million ≈ $-51.78 Million |
-0.635x | -171.79% |
| 2020-12-31 | Skr1.24 Billion ≈ $133.67 Million |
Skr-290.27 Million ≈ $-31.24 Million |
-0.234x | +60.71% |
| 2019-12-31 | Skr562.82 Million ≈ $60.57 Million |
Skr-334.77 Million ≈ $-36.03 Million |
-0.595x | -150.04% |
| 2018-12-31 | Skr859.88 Million ≈ $92.54 Million |
Skr-204.56 Million ≈ $-22.01 Million |
-0.238x | +0.05% |
| 2017-12-31 | Skr630.66 Million ≈ $67.87 Million |
Skr-150.10 Million ≈ $-16.15 Million |
-0.238x | +28.60% |
| 2016-12-31 | Skr283.69 Million ≈ $30.53 Million |
Skr-94.56 Million ≈ $-10.18 Million |
-0.333x | -21.99% |
| 2015-12-31 | Skr211.53 Million ≈ $22.76 Million |
Skr-57.80 Million ≈ $-6.22 Million |
-0.273x | +42.39% |
| 2014-12-31 | Skr49.80 Million ≈ $5.36 Million |
Skr-23.62 Million ≈ $-2.54 Million |
-0.474x | -45.75% |
| 2013-12-31 | Skr45.68 Million ≈ $4.92 Million |
Skr-14.87 Million ≈ $-1.60 Million |
-0.325x | +0.26% |
| 2012-12-31 | Skr63.24 Million ≈ $6.81 Million |
Skr-20.63 Million ≈ $-2.22 Million |
-0.326x | +58.28% |
| 2011-12-31 | Skr34.71 Million ≈ $3.74 Million |
Skr-27.14 Million ≈ $-2.92 Million |
-0.782x | -39.01% |
| 2010-12-31 | Skr32.17 Million ≈ $3.46 Million |
Skr-18.09 Million ≈ $-1.95 Million |
-0.563x | -1.64% |
| 2009-12-31 | Skr24.92 Million ≈ $2.68 Million |
Skr-13.79 Million ≈ $-1.48 Million |
-0.553x | -44.73% |
| 2008-12-31 | Skr40.73 Million ≈ $4.38 Million |
Skr-15.58 Million ≈ $-1.68 Million |
-0.382x | -- |
About Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant pa… Read more